Loading…
Loading…
PEAK (Healthpeak Properties, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PEAK and 80,000+ other tickers.
See exactly how PEAK's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PEAK and 80,000+ other tickers.
Healthpeak Properties, Inc., an S&P 500 constituent, operates as a fully integrated real estate investment trust (REIT). The company specializes in the acquisition and development of premium properties across three private-pay healthcare segments: Life Science, Medical Office, and Senior Housing. This focus is meticulously crafted to deliver stability amidst the cyclical nature of the industry. Healthpeak leverages its profound expertise in the healthcare property market, coupled with an ambitious outlook for sustained, long-term expansion.
New Linux Foundation and first open-source metadata server advances parallel file system design with an elastic architecture for AI and HPC storage at scale New Linux Foundation and first open-source metadata server advances parallel file system design with an elastic architecture for AI and HPC storage at scale
Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p
WALTHAM, Mass. and BOULDER, Colo.
The Next Evolution in F45 Training Performance Events Launches Network-Wide with Red Bull as Global Partner The Next Evolution in F45 Training Performance Events Launches Network-Wide with Red Bull as Global Partner
- PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus sunitinib combination demonstrating mPFS of 16.5 months and ORR of 46% in patients who had received prior treatment with imatinib - Cogent is expected to initiate the RTOR process immediately; completion of the PEAK NDA submission expected in April 2026 WALTHAM, Mass. and BOULDER, Colo.